PRE-MARKET | October 13, 2016 | $REGN, $ULTA, $LNN, $CARA, $WFC, $EBAY, $CSIQ, $AMZN, $GPRO, $DECK, $BW, $WGO

PRE-MARKET | October 13, 2016 | $REGN, $ULTA, $LNN, $CARA, $WFC, $EBAY, $CSIQ, $AMZN, $GPRO, $DECK, $BW, $WGO

PRE-MARKET MOVERS

 

UPGRADES

3. BMY, MRK:$MRK upgraded to Buy from Neutral at BofA/Merrill, PT $70. $BMY
7. HCA:$HCA – *MW HCA Holdings upgraded to overweight from sector weight at KeyBanc Capital
8. MSFT:$MSFT upgraded to Buy at Zacks Research – PT $64

 

DOWNGRADES

1. BMY:$BMY downgraded to Buy from Conviction Buy at Goldman Sachs

 

EARNINGS

 

Trending Social Alerts

1. OCUL:$OCUL and $REGN Collaboration To Develop Sustained Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other RetinalDiseases
2. DAL:#BREAKING: Delta Air Lines $DAL Q3 Revenue, $10.48B vs. $10.55B expected
3. TGTX:$TGTX Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall Response Rate
4. AMRS:$AMRS – $20M equity investment @ $1.40. $100M in annual revenues starting in 2017. Deal more than doubles annual revenue
7. OGXI:$OGXI halt
8. BMRN:$BMRN apparently believes by FDA’s own analysis drisa’s dystrophin data stronger than $SRPT. What ar…

 

Trending News Headlines

1. Bluebird Bio showcases upgraded gene therapy for rare blood diseases

The enhancements to Lentiglobin increase the number of cells containing corrected, functional genes that can be delivered into patients with two rare inherited blood diseases, Bluebird says.

2. Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose

1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mg Bempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and Well-Tolerated Conference …

3. Ulta Beauty Hosts Analyst and Investor Conference and Raises Third Quarter and Fiscal Year 2016 Guidance

Ulta Beauty will host its 2016 analyst and investor conference today, Thursday, October 13, 2016 from 10:00 a.m. to 3:00 p.m. in Chicago, Illinois. In conjunction with this event, the Company raised its financial guidance for the third quarter and full year 2016, and provided an update on its long term

4. Event Details | Investor Relations | Bluebird Bio

Manisha Pai

5. Press Release | Investor Relations | Bluebird Bio

– Consistently demonstrated improved vector copy number (VCN) in transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) patient cells in vitro with manufacturing Process 2 –

6. bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day | Business Wire

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic disea

7. Amazon Hiring 120,000 For The Holidays (NASDAQ:AMZN)

Amazon.com, Inc. (NASDAQ: AMZN) needs to hire 120,000 new part-time workers across its entire network to ensure a flawless and efficient shopping experience ahead of the holiday…

8. Georgi Kantchev on Twitter

“Oil at $70/b is too hot, and $50/b too cold for U.S. shale, says @CreditSuisse”

9. Amazon to hire 120,000 temporary workers for holiday season

Amazon.com Inc said it would hire more than 120,000 seasonal workers in the United States for the holiday season, 20 percent more than last year, highlighting the growing threat the e-commerce giant poses to traditional retailers.

10. Deutsche Bank alerts managers to hiring freeze: source

Deutsche Bank (DBKGn.DE) has introduced a hiring freeze as it seeks to cut costs amid a deep strategic overhaul, a source familiar with the matter told Reuters on Thursday.

Technology News

PRE-MARKET | October 12, 2016 | $ES_F, $SPY, $DB, $MNK, $IPCI, $LNG, $AAPL, $BABA, $AA

PRE-MARKET | October 12, 2016 | $ES_F, $SPY, $DB, $MNK, $IPCI, $LNG, $AAPL, $BABA, $AA

PRE-MARKET MOVERS

 

UPGRADES

1. AAPL:$AAPL upgraded to Positive on iPhone 7 strength at OTR Global
3. BABA:$BABA upgraded to Strong Buy at Vetr Inc.

 

DOWNGRADES

1. AA:$AA downgraded to Neutral at Bank of America, maintians Neutral rating at Goldman Sachs – PT cut $28 from $30

 

Trending Social Alerts
2. IPCI:$IPCI Intellipharmaceutics, Mallinckrodt $MNK Enter Exclusive Licensing Agreement for XR Drug Candidates

 

Trending News Headlines

1. AstraZeneca pulls plug on PhII asthma trial at interim analysis, sinking Synairgen’s stock | FierceBiotech

AstraZeneca has halted a Phase IIa trial of the severe asthma drug it licensed from Synairgen. The Big Pharma took action after an interim analysis raised doubts about whether the study could deliver meaningful data against its primary endpoint, throwing the future of the program into question and wiping 40% off Synairgen’s share price.

2. Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML | Business Wire

Celgene and Agios Form Diagnostic Collaborations for IDH Mutated AML

3. Apple (AAPL) PT Raised to $130 Mizuho; Sees In-Line Q4 and Upside to December Qtr

Mizuho Securities analyst Abhey Lamba previewed Apple’s (NASDAQ: AAPL) Q4 results, reiterating a Buy rating and bumping its price target to $130.00 (from $120.00).Lamba sees revenue and EPS…

4. Weyerhaeuser (WY) to Explore Options for Uruguay Business

Weyerhaeuser Company (NYSE: WY) announced the exploration of strategic alternatives for its timberlands and manufacturing…

5. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Skip to main page content

6. Stanley black & decker just hammered a nail through sears

One bidder for Sears’ Craftsman unit may have just pulled out of the race.

7. OPEC says it raises oil output, despite deal to cut

OPEC reported an increase in its oil production in September to a multi-year high and raised its forecast for 2017 non-OPEC supply growth, pointing to a larger surplus in the market next year despite the group’s deal to cut output.

Technology News

If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to ourYoutube Channel

See you in the chat room

PRE-MARKET | October 11, 2016 | $TWLO, $AAPL, $SPY, $TWTR, $YUM, $TSLA, $AA,

PRE-MARKET | October 11, 2016 | $TWLO, $AAPL, $SPY, $TWTR, $YUM, $TSLA, $AA,

PRE-MARKET MOVERS

 

UPGRADES

5. MNTA:$mnta upgraded to overweight by Barclays.
11. TWTR:$TWTR upgraded to Hold at Evercore ISI Group – PT $17
12. VA:$VA upgraded to Neutral at JP Morgan – PT raise $52.50 from $50

 

DOWNGRADES

 

EARNINGS

Trending Social Alerts

3. NBIX:$NBIX INGREZZA priority review PDUFA is 4/11/2017.
5. SUPN:$SUPN halted

 

Trending News Headlines

1. Alcoa Falls as Last Earnings Before Split Miss on Sales Slowdown

Alcoa Inc. headed for the biggest drop in a month after the 128-year-old aluminum maker’s last earnings before splitting into two companies missed estimates and it cut forecasts for prized parts businesses.

2. CNBC Now on Twitter

“LATEST: Twitter and Salesforce remain in deal talks – sources (via @davidfaber)”

3. Samsung to Permanently Discontinue Galaxy Note 7 Smartphone

Samsung said it would permanently discontinue production and sales of its embattled Galaxy Note 7 smartphone. Potential losses to Samsung could wipe out the mobile division’s operating profits for the fourth quarter, according to one estimate.

4. zach on Twitter

“$HZNP expected net sales on non-GAAP adj basis at low end of prev annc’d full yr net sales range, 272-274M”

5. Alcoa to report fiscal third-quarter earnings before the bell

Analysts expect Alcoa to report earnings of about 35 cents a share on 5.31 billion in revenue, according to Thomson Reuters.

6. Citi’s UK chief says timing of Brexit contingency plans now key dilemma

The UK head of U.S. bank Citi (C.N) said on Tuesday that the main question facing the finance industry now is when to enact contingency planning after Britain voted to leave the European Union.

7. Samsung to Permanently Discontinue Galaxy Note 7 Smartphone

The move halts production and sale of the defective premium phone.

8. Samsung Kills Off the Galaxy Note 7 Smartphone

The unprecedented move by the South Korean electronics giant is an embarrassing reversal for a respected global brand.

9. Some comment on the Twitter buyout rumours

Twitter is wildly addictive. This is well known and there are people who check twitter more obsessively than anyone checked email. Twitter…

10. Early movers: STJ, YHOO, TWTR, CAG, UBS, CBS, CAT & more

Some of the names on the move ahead of the open.

11. Twitter Is Said to Be in Continued Talks With Salesforce

The company tries to forge ahead despite a constantly shifting chess match of deal discussions and considerations.

12. Exclusive: Russia’s Rosneft boss Sechin says no to OPEC oil cap

Igor Sechin, Russia’s most influential oil executive and the head of state-controlled energy giant Rosneft (ROSN.MM), said his company will not cap oil production as part of a possible agreement with OPEC.

13. Shire said to edge closer to Radius deal – sources

Still, well-placed City sources have told little old Betaville that the London-listed company had now lined up financing from several banks, including Royal Bank of Canada and Morgan Stanley, for the potential acquisition after Radius began working with Bank of America Merrill Lynch to pursue “strategic options” (banker parlance for sale).

14. IEA Head Sees $60 Oil Prompting Surge in North American Output

Crude prices of $60 a barrel would probably trigger a strong increase in North American oil production while trimming global demand growth, the head of the International Energy Agency said.

Technology News

PRE-MARKET | October 07, 2016 | $EXEL, $AMZN, $GS, $FSLR, $HON, $DB, $TOT, $TWTR

PRE-MARKET | October 07, 2016 | $EXEL, $AMZN, $GS, $FSLR, $HON, $DB, $TOT, $TWTR

PRE-MARKET MOVERS

 

UPGRADES

6. SCYX:$SCYX upgraded to Strong Buy at WBB Securities.

 

DOWNGRADES

 

Trending Social Alerts

1. GWPH:Goldman upgrades SMID biotech to attractive. $GWPH initiated buy at GS with $189/target
2. CLVS:$CLVS down 8% –> Rucaparib 0% ORR for platinum-refractory patients, 25% ORR for platinum-resistant patients
3. SCYX:$SCYX upgraded to Strong Buy at WBB Securities.
6. INCY:$INCY – epacadostat + Keytruda in melanoma PFS rate of 74% at 6 mos., 57% at 12 mos. mPFS not yet reached. Median follow up 56 wks. #ESMO17
8. ALNY:MS $ALNY Revusiran Discontinuation Raises Key Questions; Downgrading PT $36.00 Imbalance of mortality leads
9. SAGE:@tgtxdough Renewed interest in CNS disorders has created a rich pipeline of new candidates Names recommend $AVXS $GWPH $SAGE
10. KITE:@tgtxdough Immuno-oncology continues to emerge as a cornerstone of cancer treatment. Names recommend $INCY $KITE

 

Trending News Headlines

1. Andy Biotech on Twitter

“$CLVS down 8% –> Rucaparib 0% ORR for platinum-refractory patients, 25% ORR for platinum-resistant patients”

2. Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress | Business Wire

Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at

3. Liquid Biopsy on Twitter

“$INCY $MRK #ESMO16 Update – Thoughts on ECHO-202/KEYNOTE-037 Initial melanoma PFS trend look competitive vs. (cont)

4. Payrolls in U.S. Rise 156,000 as Americans Stream Into Workforce

Employers continued to add to payrolls in September as record openings drew more Americans into the workforce and most found jobs, indicating the U.S. labor market is settling into a pace that will support the economy.

5. Data Presented at ESMO 2016 Adds to Understanding of Abraxane® as a Therapy for Patients with Historically Challenging Solid Tumors (NASDAQ:CELG)

Multiple presentations evaluate ABRAXANE alone or in combination with novel agents and novel regimens to treat mPAC, NSCLC, and MBC SUMMIT, N.J.–(BUSINESS WIRE)– …

6. Bridge and Tunnel Investor

Visit our forum at: bridgeandtunnelinvestor.com

7. Ruby Tuesday, Inc. (NYSE:RT) – Ruby Tuesday Q1 Sales Decline, Closes 95 Stores In Quarter

Shares of Ruby Tuesday, Inc. (NYSE: RT) are down following the release of its Q1 earnings after Thursday’s market close. The restaurant operator’s total revenue…

Technology News

PRE-MARKET | October 06, 2016 | $TWTR, $AAPL, $ES_F, $SPY, $YUM, $WMT, $CL_F, $TSLA, $GOOGL, $DIS, $LOW

PRE-MARKET | October 06, 2016 | $TWTR, $AAPL, $ES_F, $SPY, $YUM, $WMT, $CL_F, $TSLA, $GOOGL, $DIS, $LOW

PRE-MARKET MOVERS

 

UPGRADES

7. SCTY:$SCTY upgraded to Hold at Axiom Capital

 

DOWNGRADES

5. GS, TSLA:$TSLA Downgraded to neutral by $GS. Power Gauge bearish…sell and ignore Musk’s hype

 

Trending Social Alerts

1. TWTR:Twitter shares down nearly 18% in pre-market. Would be worst day since April 2015 if closed at these levels. $TWTR
3. WMT:Walmart will host its 22nd annual Analyst Meeting at 8AM CT, highlighting the company’s plan to win in retail. $WMT…
4. AUPH:$AUPH Complete remission rates increase to 70% at 24 weeks. Patients in remission at 8 weeks remained in remission at 24 weeks

 

Trending News Headlines

1. Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B

Arrowhead Pharmaceuticals Inc. and Spring Bank Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced an agreement to perform collaborative studies on Arrowhead’s ARC-520

2. Deutsche Bank announces extra 1,000 jobs to go in Germany

Embattled German lender Deutsche Bank announced Thursday that an extra 1,000 jobs would be lost in its home nation as part of an ongoing restructuring plan.

3. Alnylam gene-silencing drug blows up; damage could spread deep into biotech sector

Alnylam said Wednesday evening that it was scrapping development of revusiran, one of the two most advanced gene-silencing drugs in the company’s pipeline.

4. Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis

Aurinia Pharmaceuticals Inc. a clinical stage biopharmaceutical company focused on the global immunology market, today announced 24-week data in all 10 patients from the AURION study, an open-label exploratory study to assess the short-term predictors of response using voclosporin in combination with

5. US crude breaks $50 a barrel for first time since June

Oil prices were underpinned by a surprisingly large drop in U.S. inventory levels the previous day.

6. bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation

bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the agenda and speakers for its Gene Therapy Day, starting at 9:00 am ET on October 13, 2016 at Le Parker

7. Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NASDAQ:KITE)

First patient enrolled in ZUMA-6 study evaluating safety and efficacy of anti-CD19 CAR (KTE-C19) therapy in combination with anti-PD-L1 monoclonal antibody atezolizumab SANTA MONICA, Cal…

8. Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | Business Wire

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA), Celltrion, Inc. and Celltrion Healthcare today announce that the companies have entered into

9. Wal-Mart reiterates guidance, plans to slow store openings to invest in digital

Wal-Mart expects next year’s earnings to come in relatively flat as it invests more in digital and technology.

10. Wal-mart (WMT) Outlines Strategic Growth Plan; Reaffirms FY17 Outlook

At its 2016 Investment Community Meeting today, Wal-Mart Stores, Inc. (NYSE: WMT) will outline the companys strategic framework to grow by serving customers across all channels, creating a seamless…

11. Deutsche may not face German penalty over Russian trades: sources

Germany’s financial watchdog has found no evidence to date that Deutsche Bank (DBKGn.DE) violated money laundering rules in Russia, people close to matter said on Thursday, possibly relieving one headache for the country’s biggest bank.

Technology News